HK1204914A1 - Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections - Google Patents
Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infectionsInfo
- Publication number
- HK1204914A1 HK1204914A1 HK15105031.3A HK15105031A HK1204914A1 HK 1204914 A1 HK1204914 A1 HK 1204914A1 HK 15105031 A HK15105031 A HK 15105031A HK 1204914 A1 HK1204914 A1 HK 1204914A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cobicistat
- treatment
- combination therapy
- viral infections
- tenofovir alafenamide
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 title 1
- 229960002402 cobicistat Drugs 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- SVUJNSGGPUCLQZ-FQQAACOVSA-N tenofovir alafenamide fumarate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594894P | 2012-02-03 | 2012-02-03 | |
| US201261618411P | 2012-03-30 | 2012-03-30 | |
| US201261624676P | 2012-04-16 | 2012-04-16 | |
| US201261692392P | 2012-08-23 | 2012-08-23 | |
| US201261737493P | 2012-12-14 | 2012-12-14 | |
| PCT/US2013/024438 WO2013116720A1 (en) | 2012-02-03 | 2013-02-01 | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1204914A1 true HK1204914A1 (en) | 2015-12-11 |
Family
ID=47722563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15103394.9A HK1202801A1 (en) | 2012-02-03 | 2015-04-07 | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
| HK15105031.3A HK1204914A1 (en) | 2012-02-03 | 2015-05-27 | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15103394.9A HK1202801A1 (en) | 2012-02-03 | 2015-04-07 | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150105350A1 (xx) |
| EP (1) | EP2809323A1 (xx) |
| JP (1) | JP6059255B2 (xx) |
| KR (1) | KR20140119177A (xx) |
| CN (1) | CN104105484A (xx) |
| AU (3) | AU2013204727A1 (xx) |
| BR (1) | BR112014018918A8 (xx) |
| CA (1) | CA2863662A1 (xx) |
| EA (1) | EA026138B1 (xx) |
| HK (2) | HK1202801A1 (xx) |
| IL (1) | IL233874A0 (xx) |
| MD (1) | MD20140091A2 (xx) |
| MX (1) | MX2014009172A (xx) |
| NZ (1) | NZ629896A (xx) |
| WO (2) | WO2013116720A1 (xx) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2487166T (lt) | 2007-02-23 | 2016-11-10 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
| EA021377B9 (ru) | 2008-12-09 | 2015-09-30 | Джилид Сайэнс, Инк. | Модуляторы толл-подобных рецепторов |
| US8754065B2 (en) | 2011-08-16 | 2014-06-17 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| EP3038607A2 (en) * | 2013-08-29 | 2016-07-06 | Teva Pharmaceutical Industries Ltd. | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir |
| WO2015079455A2 (en) * | 2013-11-27 | 2015-06-04 | Laurus Labs Private Limited | A recycling process for preparing tenofovir alafenamide diastereomers |
| US9463194B2 (en) | 2014-02-05 | 2016-10-11 | Gilead Sciences, Inc. | Methods of treating patients co-infected with HIV and tuberculosis |
| CA2942877A1 (en) * | 2014-04-08 | 2015-10-15 | Nitzan SHAHAR | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir |
| CN105531281B (zh) * | 2014-04-21 | 2017-12-15 | 四川海思科制药有限公司 | 一种核苷类似物及其中间体的制备方法 |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| TWI806081B (zh) * | 2014-07-11 | 2023-06-21 | 美商基利科學股份有限公司 | 用於治療HIV之toll樣受體調節劑 |
| UY36298A (es) | 2014-09-16 | 2016-04-29 | Gilead Science Inc | Formas sólidas de un modulador del receptor tipo toll |
| CN105237571B (zh) * | 2014-11-28 | 2018-03-09 | 成都苑东生物制药股份有限公司 | 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐 |
| EP3226973A4 (en) * | 2014-12-04 | 2018-05-30 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| RS62434B1 (sr) | 2014-12-26 | 2021-11-30 | Univ Emory | Antivirusni n4-hidroksicitidin derivati |
| WO2016108205A1 (en) * | 2015-01-03 | 2016-07-07 | Mylan Laboratories Limited | Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof |
| ES2844848T3 (es) | 2015-04-21 | 2021-07-22 | Eiger Biopharmaceuticals Inc | Composiciones farmacéuticas que comprenden Lonafarnib y Ritonavir |
| CN104817593B (zh) * | 2015-04-27 | 2016-11-16 | 广州同隽医药科技有限公司 | 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺 |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| WO2017004244A1 (en) * | 2015-06-30 | 2017-01-05 | Gilead Sciences, Inc. | Pharmaceutical formulations comprising tenofovir and emtricitabine |
| WO2017023694A1 (en) | 2015-08-03 | 2017-02-09 | Pop Test Oncology Llc | Pharmaceutical compositions and methods |
| CN105153231A (zh) * | 2015-08-28 | 2015-12-16 | 浙江车头制药股份有限公司 | 一种一苯基pmpa的制备方法 |
| SG11201802983TA (en) * | 2015-11-09 | 2018-05-30 | Gilead Sciences Inc | Therapeutic compositions for treatment of human immunodeficiency virus |
| JP7085998B2 (ja) * | 2016-02-12 | 2022-06-17 | シプラ・リミテッド | 抗レトロウイルス薬及び薬物動態学的エンハンサーを含む医薬組成物 |
| CN107179355B (zh) * | 2016-03-11 | 2021-08-10 | 广东东阳光药业有限公司 | 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法 |
| US10449208B2 (en) * | 2016-08-25 | 2019-10-22 | Merck Sharp & Dohme Corp. | Antiviral prodrugs of tenofovir |
| CN108070003A (zh) * | 2016-12-02 | 2018-05-25 | 上海博志研新药物技术有限公司 | 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用 |
| US20190374557A1 (en) * | 2017-02-28 | 2019-12-12 | Alexandre Vasilievich Ivachtchenko | Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof |
| RU2659388C1 (ru) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
| CN106928277A (zh) * | 2017-03-16 | 2017-07-07 | 江苏诚信药业有限公司 | 一种替诺福韦艾拉酚胺合成的工艺方法 |
| US11191763B2 (en) | 2017-03-20 | 2021-12-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | HIV post-exposure prophylaxis |
| US11234981B2 (en) * | 2017-04-18 | 2022-02-01 | Cipla Limited | Combination therapy for use in treating retroviral infections |
| RU2659693C1 (ru) * | 2017-06-30 | 2018-07-03 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции |
| EP3700573A1 (en) * | 2017-10-24 | 2020-09-02 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
| CN111372592A (zh) | 2017-12-07 | 2020-07-03 | 埃默里大学 | N4-羟基胞苷及衍生物和与其相关的抗病毒用途 |
| CN110305163A (zh) * | 2018-03-27 | 2019-10-08 | 北京济美堂医药研究有限公司 | 替诺福韦艾拉酚胺半富马酸盐的制备方法 |
| CN108484672A (zh) * | 2018-05-23 | 2018-09-04 | 中国药科大学制药有限公司 | 磷丙替诺福韦的手性拆分方法 |
| CN109081853A (zh) * | 2018-09-03 | 2018-12-25 | 南京正大天晴制药有限公司 | 一种磷丙替诺福韦有关物质的制备方法 |
| EP3989956A1 (en) * | 2019-06-28 | 2022-05-04 | Anhui Ronghang Biotech Development Co., Ltd. | Compositions and methods for treatment of hepatitis b virus infection |
| WO2021015818A1 (en) | 2019-07-19 | 2021-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv pre-exposure prophylaxis |
| CN111606949A (zh) * | 2020-03-13 | 2020-09-01 | 浙江车头制药股份有限公司 | 一种磷丙替诺福韦杂质的制备方法 |
| CN111303209A (zh) * | 2020-03-21 | 2020-06-19 | 石家庄龙泽制药股份有限公司 | 一种丙酚替诺福韦降解杂质的制备方法 |
| WO2024196814A1 (en) | 2023-03-17 | 2024-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for treatment of age-related macular degeneration |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB453061A (en) | 1935-03-23 | 1936-09-04 | Charles Howard Twigg | Improvements in and relating to gas heated geysers and water heaters |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| AU2001282941C1 (en) * | 2000-07-21 | 2016-12-22 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| DE10153078A1 (de) | 2001-10-30 | 2003-05-22 | Degussa | Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen |
| ATE398455T1 (de) | 2003-01-14 | 2008-07-15 | Gilead Sciences Inc | Zusammensetzungen und verfahren zur antiviralen kombinationstherapie |
| LT2487166T (lt) * | 2007-02-23 | 2016-11-10 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
| US8354421B2 (en) | 2007-06-29 | 2013-01-15 | Korea Research Insitute Of Chemical Technology | HIV reverse transcriptase inhibitors |
| SG10201706215UA (en) * | 2009-02-06 | 2017-08-30 | Gilead Sciences Inc | Tablets for combination therapy |
| US8754065B2 (en) * | 2011-08-16 | 2014-06-17 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
-
2013
- 2013-02-01 KR KR20147024291A patent/KR20140119177A/ko not_active Application Discontinuation
- 2013-02-01 WO PCT/US2013/024438 patent/WO2013116720A1/en active Application Filing
- 2013-02-01 CA CA 2863662 patent/CA2863662A1/en not_active Abandoned
- 2013-02-01 AU AU2013204727A patent/AU2013204727A1/en not_active Abandoned
- 2013-02-01 NZ NZ629896A patent/NZ629896A/en unknown
- 2013-02-01 BR BR112014018918A patent/BR112014018918A8/pt not_active IP Right Cessation
- 2013-02-01 EP EP13704863.3A patent/EP2809323A1/en not_active Withdrawn
- 2013-02-01 JP JP2014555783A patent/JP6059255B2/ja active Active
- 2013-02-01 MD MDA20140091A patent/MD20140091A2/ro not_active Application Discontinuation
- 2013-02-01 EA EA201491287A patent/EA026138B1/ru unknown
- 2013-02-01 AU AU2013204731A patent/AU2013204731C1/en active Active
- 2013-02-01 MX MX2014009172A patent/MX2014009172A/es unknown
- 2013-02-01 WO PCT/US2013/024451 patent/WO2013116730A1/en active Application Filing
- 2013-02-01 CN CN201380007670.XA patent/CN104105484A/zh active Pending
- 2013-02-01 US US14/376,116 patent/US20150105350A1/en not_active Abandoned
-
2014
- 2014-07-30 IL IL233874A patent/IL233874A0/en unknown
-
2015
- 2015-04-07 HK HK15103394.9A patent/HK1202801A1/xx unknown
- 2015-05-27 HK HK15105031.3A patent/HK1204914A1/xx unknown
-
2016
- 2016-06-02 AU AU2016203666A patent/AU2016203666A1/en not_active Abandoned
- 2016-10-03 US US15/284,105 patent/US20170056423A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013204731C1 (en) | 2017-08-31 |
| KR20140119177A (ko) | 2014-10-08 |
| JP6059255B2 (ja) | 2017-01-11 |
| EA201491287A1 (ru) | 2015-04-30 |
| NZ629896A (en) | 2016-03-31 |
| IL233874A0 (en) | 2014-09-30 |
| AU2013204731B2 (en) | 2016-03-03 |
| AU2016203666A1 (en) | 2016-06-23 |
| CA2863662A1 (en) | 2013-08-08 |
| WO2013116730A1 (en) | 2013-08-08 |
| US20150105350A1 (en) | 2015-04-16 |
| HK1202801A1 (en) | 2015-10-09 |
| EP2809323A1 (en) | 2014-12-10 |
| BR112014018918A8 (pt) | 2017-07-11 |
| WO2013116720A1 (en) | 2013-08-08 |
| CN104105484A (zh) | 2014-10-15 |
| MX2014009172A (es) | 2014-08-27 |
| MD20140091A2 (ro) | 2015-01-31 |
| US20170056423A1 (en) | 2017-03-02 |
| AU2013204727A1 (en) | 2013-08-22 |
| BR112014018918A2 (xx) | 2017-06-20 |
| JP2015505565A (ja) | 2015-02-23 |
| EA026138B1 (ru) | 2017-03-31 |
| AU2013204731A1 (en) | 2013-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1204914A1 (en) | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections | |
| IL253225B (en) | Sulfamoyl-arylamides and their use as drugs to treat jaundice b | |
| HK1216176A1 (zh) | 用於治療增殖性和自身免疫疾病的非對稱吡咯並苯並二氮雜卓二聚物 | |
| ZA201500921B (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases | |
| HK1209100A1 (en) | N-substituted benzamides and their use in the treatment of pain n- | |
| HK1221178A1 (zh) | 卡博替尼劑型及其在癌症治療中的使用 | |
| HUE036387T2 (hu) | Pirrolopirimidin származékok vírusfertõzések kezelésében való felhasználásra | |
| HK1210463A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| HK1199712A1 (en) | 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis 18--67--3--17--4--2117- | |
| HK1222818A1 (zh) | 左西替利嗪和孟魯司特在治療創傷性損傷中的用途 | |
| GB2515439B (en) | Vesicular formulations for use in the treatment of reduced mobility | |
| GB201222455D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease | |
| ZA201501503B (en) | Bio-inoculant and use thereof for treatment of effluents | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| PL2872176T3 (pl) | Karboranyloporfiryny do stosowania w leczeniu raka | |
| EP2744786A4 (en) | SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER | |
| HK1209073A1 (en) | Plod-2 stimulators and their use in the treatment of skin plod-2 |